Keytruda improves survival in first-line squamous NSCLC

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab plus chemotherapy met the primary endpoints of improving progression-free survival (PFS) and overall survival (OS) in the Phase III KEYNOTE-407 trial as first-line treatment of metastatic squamous non-small cell lung cancer. The company plans to present the data at the American Society of Clinical Oncology meeting in Chicago.

An sBLA for the humanized IgG4 mAb against PD-1 is under FDA review for the indication...